'No compelling case for cuts': Wall Street's takeaways from Kevin Warsh's testimony

The immediate market implication is not about rate cuts per se, but about the repricing of the policy path distribution. A Fed chair nominee who signals tolerance for tighter-for-longer conditions raises the odds of higher real yields at the front end, which is more damaging for duration-sensitive assets than a single cut delay. That is a subtle but important shift: the market should price less easing optionality, not necessarily a full hawkish regime change.

Financials are a relative beneficiary only if the move in yields is driven by a steeper curve rather than a pure front-end selloff. In a flat-to-inverted re-pricing, banks like BAC face a mixed setup: deposit beta pressure eases, but loan demand and capital markets activity can slow. GS is less rate-sensitive on earnings, but a tougher Fed narrative can still weigh on underwriting, M&A timing, and fee pools, especially if equity multiples compress.

IBKR is the cleaner expression because its economics benefit from volatility, higher rates on customer cash, and elevated trading engagement. The second-order effect is that a more hawkish nominee may actually extend the window of elevated rates/volatility long enough to support brokerage monetization even if equities wobble. The market may be underestimating how much a credibility-driven Fed can keep real rates restrictive even under political pressure.

The key contrarian risk is political and procedural, not macro: confirmation odds may deteriorate before policy even matters. If the committee process stalls or the Powell investigation becomes the gating item, the whole curve trade can unwind quickly as investors revert to a more dovish successor path. That makes this a two-step event: near-term headline risk around confirmation, followed by medium-term repricing of the Fed reaction function if Warsh advances.